Basic Research Sector Clinical Pharmacogenomics and Drug Discovery Group
Group Introduction
Leader:
Professor Masahiro Hiratsuka (Graduate School of Pharmaceutical Sciences)
This group aims to develop and publish pharmacokinetics prediction panels based on genomic information, and promotes the development and clinical implementation of personalized pharmacotherapy through pharmacogenomics analysis. By utilizing the whole-genome reference panel created by the Tohoku Medical Megabank Organization, the group produces and evaluates approximately 1,000 types of recombinant variant enzymes, such as CYP1A2, CYP2C9, and DPYD. By identifying rare variants that affect drug-metabolizing enzyme activity, the group contributes significantly to the advancement of personalized medicine.
Clinical Pharmacogenomics and Drug Discovery Group Results
Main Results
- 医薬品の代謝反応を従来よりも高感度で解析できる薬物代謝酵素 - 哺乳動物細胞発現系の開発に成功
- 5-FU系抗がん剤の重篤副作用発現に影響する薬物代謝酵素DPYDの日本人集団における遺伝的特性を解明
